lenalidomide has been researched along with Cardiotoxicity in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asante, D; Buadi, FK; Herrmann, J; Lerman, A; Reneau, JC; Sangaralingham, LR; van Houten, H | 1 |
1 other study(ies) available for lenalidomide and Cardiotoxicity
| Article | Year |
|---|---|
Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiotoxicity; Heart Diseases; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Propensity Score; Proportional Hazards Models; Risk; Thalidomide | 2017 |